Bullous Sweet syndrome following SARS‐CoV‐2 Oxford AstraZeneca vaccine

Žagar, Tina; Hlača, Nika; Brajac, Ines; Prpić‐Massari, Larisa; Peternel, Sandra; Kaštelan, Marija

doi:10.1111/bjd.20876

prikaz prve stranice dokumenta Bullous Sweet syndrome following SARS‐CoV‐2 Oxford AstraZeneca vaccine

Access restricted to all Croatian higher education institution's students and staff

Scientific paper - Case study

Bullous Sweet syndrome following SARS‐CoV‐2 Oxford AstraZeneca vaccine

British Journal of Dermatology, 186 (2021), 3; 110. https://doi.org/10.1111/bjd.20876

Žagar, Tina; Hlača, Nika; Brajac, Ines; Prpić‐Massari, Larisa; Peternel, Sandra; Kaštelan, Marija

Request a copy
of the document

Linked objects

COVID-19 | Virtual collection

Cite this document

APA 6th Edition

Žagar, T., Hlača, N., Brajac, I., Prpić‐Massari, L., Peternel, S. & Kaštelan, M. (2021). Bullous Sweet syndrome following SARS‐CoV‐2 Oxford AstraZeneca vaccine. British Journal of Dermatology, 186. (3). doi: 10.1111/bjd.20876

MLA 8th Edition

Žagar, Tina, et al. "Bullous Sweet syndrome following SARS‐CoV‐2 Oxford AstraZeneca vaccine." British Journal of Dermatology, vol. 186, no. 3, 2021. https://doi.org/10.1111/bjd.20876

Chicago 17th Edition

Žagar, Tina, Nika Hlača, Ines Brajac, Larisa Prpić‐Massari, Sandra Peternel and Marija Kaštelan. "Bullous Sweet syndrome following SARS‐CoV‐2 Oxford AstraZeneca vaccine." British Journal of Dermatology 186, no. 3 (2021). https://doi.org/10.1111/bjd.20876

Harvard

Žagar, T., et al. (2021) 'Bullous Sweet syndrome following SARS‐CoV‐2 Oxford AstraZeneca vaccine', British Journal of Dermatology, 186(3). doi: 10.1111/bjd.20876

Vancouver

Žagar T, Hlača N, Brajac I, Prpić‐Massari L, Peternel S, Kaštelan M. Bullous Sweet syndrome following SARS‐CoV‐2 Oxford AstraZeneca vaccine. British Journal of Dermatology [Internet]. 2021 November 24 [cited 2024 November 19];186(3). doi: 10.1111/bjd.20876

IEEE

T. Žagar, N. Hlača, I. Brajac, L. Prpić‐Massari, S. Peternel and M. Kaštelan, "Bullous Sweet syndrome following SARS‐CoV‐2 Oxford AstraZeneca vaccine", British Journal of Dermatology, vol. 186, no. 3, November 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:079713. [Accessed: 19 November 2024]

Cite this item: https://urn.nsk.hr/urn:nbn:hr:184:079713

Please login to the repository to save this object to your list.

Metadata

Title (english)	Bullous Sweet syndrome following SARS‐CoV‐2 Oxford AstraZeneca vaccine
Author	Tina Žagar
Author	Nika Hlača
Author	Ines Brajac
Author	Larisa Prpić‐Massari
Author	Sandra Peternel
Author	Marija Kaštelan
Author's institution	University of Rijeka Faculty of Medicine (Department of Dermatovenerology)
Scientific / art field, discipline and subdiscipline	BIOMEDICINE AND HEALTHCARE Clinical Medical Sciences Dermatovenerology
Language	english
Publication type	Scientific paper - Case study
Publication status	Published
Peer review	Peer review - international
Publication version	Published version
Journal title	British Journal of Dermatology
Numbering	vol. 186, no. 3, 110
p-ISSN	0007-0963
e-ISSN	1365-2133
DOI	https://doi.org/10.1111/bjd.20876
URN:NBN	urn:nbn:hr:184:079713
Publication	2021-11-24
Document URL	https://onlinelibrary.wiley.com/doi/10.1111/bjd.20876
Type of resource	Text
Access conditions	Restricted access
Terms of use
Created on	2022-03-10 22:11:57